Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TSHA | US
-0.04
-1.95%
Healthcare
Biotechnology
30/06/2024
04/10/2024
2.01
2.05
2.09
2.01
Taysha Gene Therapies Inc. a gene therapy company focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas Texas.
View LessLow Market Beta (-0.4 to 0.8)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.1%1 month
63.1%3 months
63.1%6 months
90.0%-
-
3.90
0.53
0.29
-0.61
24.02
-
-75.72M
417.91M
417.91M
-
-1.92K
-
-53.60
-318.69
17.01
12.77
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.22
Range1M
0.38
Range3M
0.60
Rel. volume
0.75
Price X volume
2.84M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Quanterix Corporation | QTRX | Biotechnology | 11.9 | 456.71M | -4.80% | n/a | 11.75% |
Mind Medicine (MindMed) Inc. Subordinate Voting Shares | MNMD | Biotechnology | 5.57 | 456.67M | 0.36% | n/a | 12.00% |
Alector Inc | ALEC | Biotechnology | 4.62 | 449.62M | 2.67% | n/a | 23.98% |
Xeris Pharmaceuticals Inc | XERS | Biotechnology | 2.98 | 444.02M | 2.41% | n/a | -1398.96% |
Absci Corporation Common Stock | ABSI | Biotechnology | 3.88 | 440.60M | 2.11% | n/a | 6.02% |
Foghorn Therapeutics Inc | FHTX | Biotechnology | 7.83 | 433.22M | -6.00% | n/a | -285.69% |
Esperion Therapeutics Inc | ESPR | Biotechnology | 2.16 | 423.85M | 18.68% | n/a | -161.71% |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5 | 423.12M | 4.17% | n/a | 13.27% |
LRMR | LRMR | Biotechnology | 6.65 | 408.81M | 5.72% | n/a | 2.65% |
Sage Therapeutics Inc | SAGE | Biotechnology | 6.64 | 405.37M | -4.87% | n/a | 0.22% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.61 | 0.76 | Cheaper |
Ent. to Revenue | 24.02 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.90 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 63.07 | 74.67 | Par |
Debt to Equity | 0.53 | -1.82 | Expensive |
Debt to Assets | 0.29 | 0.26 | Par |
Market Cap | 417.91M | 3.73B | Emerging |